{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:42:20Z","timestamp":1790242940980,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T00:00:00Z","timestamp":1557360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Small molecules that disrupt leukocyte trafficking have proven effective in treating patients with multiple sclerosis (MS). We previously reported that chemerin receptor chemokine-like receptor 1 (CMKLR1) is required for maximal clinical and histological experimental autoimmune encephalomyelitis (EAE); and identified CMKLR1 small molecule antagonist 2-(\u03b1-naphthoyl) ethyltrimethylammonium iodide (\u03b1-NETA) that significantly suppressed disease onset <jats:italic>in vivo<\/jats:italic>. Here we directly compared \u03b1-NETA versus FDA-approved MS drug Tecfidera for clinical efficacy in EAE; characterized key safety\/toxicity parameters for \u03b1-NETA; identified structure-activity relationships among \u03b1-NETA domains and CMKLR1 inhibition; and evaluated improved \u03b1-NETA analogs for <jats:italic>in vivo<\/jats:italic> efficacy. \u03b1-NETA proved safe and superior to Tecfidera in suppressing clinical EAE. In addition, we discovered structurally differentiated \u03b1-NETA analogs (primarily ortho- or para-methoxy substitutions) with significantly improved target potency <jats:italic>in vitro<\/jats:italic> and improved efficacy <jats:italic>in vivo<\/jats:italic>. These findings suggest that \u03b1-NETA-based CMKLR1 inhibitors may prove safe and effective in treating demyelinating diseases and potentially other autoimmune disorders.<\/jats:p>","DOI":"10.1038\/s41598-019-43428-8","type":"journal-article","created":{"date-parts":[[2019,5,9]],"date-time":"2019-05-09T10:59:00Z","timestamp":1557399540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Novel CMKLR1 Inhibitors for Application in Demyelinating Disease"],"prefix":"10.1038","volume":"9","author":[{"given":"Vineet","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"LaJevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallesh","family":"Pandrala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sam A.","family":"Jacobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay V.","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Zabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,5,9]]},"reference":[{"key":"43428_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1056\/NEJMct1101691","volume":"366","author":"D Pelletier","year":"2012","unstructured":"Pelletier, D. & Hafler, D. A. Fingolimod for multiple sclerosis. N Engl J Med 366, 339\u2013347, https:\/\/doi.org\/10.1056\/NEJMct1101691 (2012).","journal-title":"N Engl J Med"},{"key":"43428_CR2","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1038\/ni0901-762","volume":"2","author":"L Steinman","year":"2001","unstructured":"Steinman, L. Multiple sclerosis: a two-stage disease. Nat Immunol 2, 762\u2013764 (2001).","journal-title":"Nat Immunol"},{"key":"43428_CR3","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1136\/jim-2016-000339","volume":"65","author":"DL Vargas","year":"2017","unstructured":"Vargas, D. L. & Tyor, W. R. Update on disease-modifying therapies for multiple sclerosis. Journal of investigative medicine: the official publication of the American Federation for Clinical Research 65, 883\u2013891, https:\/\/doi.org\/10.1136\/jim-2016-000339 (2017).","journal-title":"Journal of investigative medicine: the official publication of the American Federation for Clinical Research"},{"key":"43428_CR4","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1146\/annurev-pathol-012513-104640","volume":"10","author":"BA Zabel","year":"2015","unstructured":"Zabel, B. A., Rott, A. & Butcher, E. C. Leukocyte chemoattractant receptors in human disease pathogenesis. Annual review of pathology 10, 51\u201381, https:\/\/doi.org\/10.1146\/annurev-pathol-012513-104640 (2015).","journal-title":"Annual review of pathology"},{"key":"43428_CR5","doi-asserted-by":"publisher","unstructured":"Baharnoori, M., Mahajan, R., Solomon, I. H., Pinkus, G. & Houtchens, M. Fingolimod-Associated Intracerebral Lymphoproliferative Disorder. American journal of therapeutics, https:\/\/doi.org\/10.1097\/MJT.0000000000000694 (2017).","DOI":"10.1097\/MJT.0000000000000694"},{"key":"43428_CR6","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jocn.2017.10.077","volume":"48","author":"Z Nitsan","year":"2018","unstructured":"Nitsan, Z. et al. Mycosis fungoides - A cutaneous lymphoproliferative disorder in a patient treated with fingolimod for multiple sclerosis. Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia 48, 102\u2013103, https:\/\/doi.org\/10.1016\/j.jocn.2017.10.077 (2018).","journal-title":"Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia"},{"key":"43428_CR7","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1177\/1352458515597568","volume":"22","author":"AP Samaraweera","year":"2016","unstructured":"Samaraweera, A. P., Cohen, S. N., Akay, E. M. & Evangelou, N. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis. Multiple sclerosis 22, 122\u2013124, https:\/\/doi.org\/10.1177\/1352458515597568 (2016).","journal-title":"Multiple sclerosis"},{"key":"43428_CR8","first-page":"1","volume":"3","author":"BA Zabel","year":"2014","unstructured":"Zabel, B. A. et al. Chemerin regulation and role in host defense. American journal of clinical and experimental immunology 3, 1\u201319 (2014).","journal-title":"American journal of clinical and experimental immunology"},{"key":"43428_CR9","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1084\/jem.20030382","volume":"198","author":"V Wittamer","year":"2003","unstructured":"Wittamer, V. et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 198, 977\u2013985, https:\/\/doi.org\/10.1084\/jem.20030382 (2003).","journal-title":"J. Exp. Med."},{"key":"43428_CR10","doi-asserted-by":"publisher","first-page":"34661","DOI":"10.1074\/jbc.M504868200","volume":"280","author":"BA Zabel","year":"2005","unstructured":"Zabel, B. A. et al. Chemerin activation by serine proteases of the coagulation, fibrinolytic, and inflammatory cascades. J Biol Chem 280, 34661\u201334666, https:\/\/doi.org\/10.1074\/jbc.M504868200 (2005).","journal-title":"J Biol Chem"},{"key":"43428_CR11","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.exphem.2006.03.011","volume":"34","author":"BA Zabel","year":"2006","unstructured":"Zabel, B. A. et al. Chemokine-like receptor 1 expression by macrophages in vivo: Regulation by TGF-B and TLR ligands. Exp. Hematol. 34, 1106\u20131114 (2006).","journal-title":"Exp. Hematol."},{"key":"43428_CR12","doi-asserted-by":"publisher","first-page":"6717","DOI":"10.4049\/jimmunol.0803435","volume":"183","author":"KL Graham","year":"2009","unstructured":"Graham, K. L. et al. Chemokine-Like Receptor-1 Expression by Central Nervous System-Infiltrating Leukocytes and Involvement in a Model of Autoimmune Demyelinating Disease. J Immunol 183, 6717\u20136723, https:\/\/doi.org\/10.4049\/jimmunol.0803435 (2009).","journal-title":"J Immunol"},{"key":"43428_CR13","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/NEN.0b013e31816fc975","volume":"67","author":"R Lande","year":"2008","unstructured":"Lande, R. et al. Plasmacytoid dendritic cells in multiple sclerosis: Intracerebral recruitment and impaired maturation response to interferon-b. J. Neuropathol. Exp. Neurol. 67, 388\u2013401 (2008).","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"43428_CR14","doi-asserted-by":"publisher","first-page":"e112925","DOI":"10.1371\/journal.pone.0112925","volume":"9","author":"KL Graham","year":"2014","unstructured":"Graham, K. L. et al. A novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory disease. PLoS One 9, e112925, https:\/\/doi.org\/10.1371\/journal.pone.0112925 (2014).","journal-title":"PLoS One"},{"key":"43428_CR15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1007\/s00204-008-0332-8","volume":"82","author":"O Pelkonen","year":"2008","unstructured":"Pelkonen, O. et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Archives of toxicology 82, 667\u2013715, https:\/\/doi.org\/10.1007\/s00204-008-0332-8 (2008).","journal-title":"Archives of toxicology"},{"issue":"2","key":"43428_CR16","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/med.21445","volume":"38","author":"Subha Kalyaanamoorthy","year":"2017","unstructured":"Kalyaanamoorthy, S. & Barakat, K. H. Development of Safe Drugs: The hERG Challenge. Medicinal research reviews, https:\/\/doi.org\/10.1002\/med.21445 (2017).","journal-title":"Medicinal Research Reviews"},{"key":"43428_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/1758-2946-3-51","volume":"3","author":"P McCarren","year":"2011","unstructured":"McCarren, P., Springer, C. & Whitehead, L. An investigation into pharmaceutically relevant mutagenicity data and the influence on Ames predictive potential. Journal of cheminformatics 3, 51, https:\/\/doi.org\/10.1186\/1758-2946-3-51 (2011).","journal-title":"Journal of cheminformatics"},{"key":"43428_CR18","first-page":"103","volume":"13","author":"W Schweckendiek","year":"1959","unstructured":"Schweckendiek, W. Treatment of psoriasis vulgaris. Medizinische Monatsschrift 13, 103\u2013104 (1959).","journal-title":"Medizinische Monatsschrift"},{"key":"43428_CR19","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3389\/fneur.2018.00005","volume":"9","author":"EA Mills","year":"2018","unstructured":"Mills, E. A., Ogrodnik, M. A., Plave, A. & Mao-Draayer, Y. Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Frontiers in neurology 9, 5, https:\/\/doi.org\/10.3389\/fneur.2018.00005 (2018).","journal-title":"Frontiers in neurology"},{"key":"43428_CR20","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.1172\/JCI72151","volume":"124","author":"H Chen","year":"2014","unstructured":"Chen, H. et al. Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate\u2019s protective effect in EAE. The Journal of clinical investigation 124, 2188\u20132192, https:\/\/doi.org\/10.1172\/JCI72151 (2014).","journal-title":"The Journal of clinical investigation"},{"key":"43428_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jaut.2015.08.014","volume":"67","author":"FV Duraes","year":"2016","unstructured":"Duraes, F. V. et al. pDC therapy induces recovery from EAE by recruiting endogenous pDC to sites of CNS inflammation. Journal of autoimmunity 67, 8\u201318, https:\/\/doi.org\/10.1016\/j.jaut.2015.08.014 (2016).","journal-title":"Journal of autoimmunity"},{"key":"43428_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2157-7536.1000191","volume":"9","author":"L Xue","year":"2018","unstructured":"Xue, L. et al. Alleviation of Diet-Induced Fat Accumulation by a Small Molecule CMKLR1 Antagonist in Mice. J Steroid Horm Sci 9, 1\u20137, https:\/\/doi.org\/10.4172\/2157-7536.1000191 (2018).","journal-title":"J Steroid Horm Sci"},{"key":"43428_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.bbi.2018.02.015","volume":"70","author":"Y Zhang","year":"2018","unstructured":"Zhang, Y. et al. Chemerin suppresses neuroinflammation and improves neurological recovery via CaMKK2\/AMPK\/Nrf2 pathway after germinal matrix hemorrhage in neonatal rats. Brain, behavior, and immunity 70, 179\u2013193, https:\/\/doi.org\/10.1016\/j.bbi.2018.02.015 (2018).","journal-title":"Brain, behavior, and immunity"},{"key":"43428_CR24","doi-asserted-by":"publisher","first-page":"95135","DOI":"10.18632\/oncotarget.19619","volume":"8","author":"C Tummler","year":"2017","unstructured":"Tummler, C. et al. Inhibition of chemerin\/CMKLR1 axis in neuroblastoma cells reduces clonogenicity and cell viability in vitro and impairs tumor growth in vivo. Oncotarget 8, 95135\u201395151, https:\/\/doi.org\/10.18632\/oncotarget.19619 (2017).","journal-title":"Oncotarget"},{"key":"43428_CR25","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1084\/jem.20112124","volume":"209","author":"RK Pachynski","year":"2012","unstructured":"Pachynski, R. K. et al. The chemoattractant chemerin suppresses melanoma by recruiting natural killer cell antitumor defenses. The Journal of experimental medicine 209, 1427\u20131435, https:\/\/doi.org\/10.1084\/jem.20112124 (2012).","journal-title":"The Journal of experimental medicine"},{"key":"43428_CR26","first-page":"879","volume":"57","author":"W Lin","year":"2011","unstructured":"Lin, W., Chen, Y. L., Jiang, L. & Chen, J. K. Reduced expression of chemerin is associated with a poor prognosis and a lowed infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma. Clinical laboratory 57, 879\u2013885 (2011).","journal-title":"Clinical laboratory"},{"key":"43428_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep31247","volume":"6","author":"R Kumar","year":"2016","unstructured":"Kumar, R., Langstrom, B. & Darreh-Shori, T. Novel ligands of Choline Acetyltransferase designed by in silico molecular docking, hologram QSAR and lead optimization. Scientific reports 6, 31247, https:\/\/doi.org\/10.1038\/srep31247 (2016).","journal-title":"Scientific reports"},{"key":"43428_CR28","first-page":"72","volume":"245","author":"BV Sastry","year":"1988","unstructured":"Sastry, B. V., Jaiswal, N., Owens, L. K., Janson, V. E. & Moore, R. D. 2-(alpha-Naphthoyl)ethyltrimethylammonium iodide and its beta-isomer: new selective, stable and fluorescent inhibitors of choline acetyltransferase. The Journal of pharmacology and experimental therapeutics 245, 72\u201380 (1988).","journal-title":"The Journal of pharmacology and experimental therapeutics"},{"issue":"3","key":"43428_CR29","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1007\/s12640-018-9902-6","volume":"34","author":"Aleksander A. Aleksandrov","year":"2018","unstructured":"Aleksandrov, A. A. et al. Identification of TAAR5 Agonist Activity of Alpha-NETA and Its Effect on Mismatch Negativity Amplitude in Awake Rats. Neurotoxicity research, https:\/\/doi.org\/10.1007\/s12640-018-9902-6 (2018).","journal-title":"Neurotoxicity Research"},{"key":"43428_CR30","doi-asserted-by":"publisher","first-page":"4777","DOI":"10.1073\/pnas.1603907113","volume":"113","author":"U Schulze-Topphoff","year":"2016","unstructured":"Schulze-Topphoff, U. et al. Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2. Proceedings of the National Academy of Sciences of the United States of America 113, 4777\u20134782, https:\/\/doi.org\/10.1073\/pnas.1603907113 (2016).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"43428_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1111\/j.1365-2249.2006.03094.x","volume":"145","author":"S Schilling","year":"2006","unstructured":"Schilling, S., Goelz, S., Linker, R., Luehder, F. & Gold, R. Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clinical and experimental immunology 145, 101\u2013107, https:\/\/doi.org\/10.1111\/j.1365-2249.2006.03094.x (2006).","journal-title":"Clinical and experimental immunology"},{"key":"43428_CR32","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/acn3.251","volume":"2","author":"Y Kihara","year":"2015","unstructured":"Kihara, Y., Groves, A., Rivera, R. R. & Chun, J. Dimethyl fumarate inhibits integrin alpha4 expression in multiple sclerosis models. Annals of clinical and translational neurology 2, 978\u2013983, https:\/\/doi.org\/10.1002\/acn3.251 (2015).","journal-title":"Annals of clinical and translational neurology"},{"key":"43428_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.bbr.2015.12.006","volume":"300","author":"NM de Bruin","year":"2016","unstructured":"de Bruin, N. M. et al. Multiple rodent models and behavioral measures reveal unexpected responses to FTY720 and DMF in experimental autoimmune encephalomyelitis. Behavioural brain research 300, 160\u2013174, https:\/\/doi.org\/10.1016\/j.bbr.2015.12.006 (2016).","journal-title":"Behavioural brain research"},{"key":"43428_CR34","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.yrtph.2016.07.011","volume":"80","author":"RH Adamson","year":"2016","unstructured":"Adamson, R. H. The acute lethal dose 50 (LD50) of caffeine in albino rats. Regulatory toxicology and pharmacology: RTP 80, 274\u2013276, https:\/\/doi.org\/10.1016\/j.yrtph.2016.07.011 (2016).","journal-title":"Regulatory toxicology and pharmacology: RTP"},{"issue":"5","key":"43428_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s11684-017-0577-9","volume":"12","author":"Xuezhou Yang","year":"2018","unstructured":"Yang, X. et al. Role of chemerin\/CMKLR1 in the maintenance of early pregnancy. Frontiers of medicine, https:\/\/doi.org\/10.1007\/s11684-017-0577-9 (2018).","journal-title":"Frontiers of Medicine"},{"key":"43428_CR36","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1124\/dmd.112.050500","volume":"41","author":"J Bentz","year":"2013","unstructured":"Bentz, J. et al. Variability in P-glycoprotein inhibitory potency (IC(5)(0)) using various in vitro experimental systems: implications for universal digoxin drug-drug interaction risk assessment decision criteria. Drug metabolism and disposition: the biological fate of chemicals 41, 1347\u20131366, https:\/\/doi.org\/10.1124\/dmd.112.050500 (2013).","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43428-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43428-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T09:27:34Z","timestamp":1671269254000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-43428-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["43428"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-43428-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,9]]},"assertion":[{"value":"13 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 April 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Dr. Kumar, Dr. LaJevic, Dr. Pandrala, Sam Jacobo, and Dr. Malhotra declare no competing interests. Dr. Zabel is an inventor on US Patent No. #9,265,738 titled, \u201cSmall Molecule CMKLR1 Antagonists in Demyelinating Disease\u201d by Graham KL, Zhang JV, Butcher EC, Zabel BA, February 2016. Dr. Zabel is also an inventor in US Patent No. #8,038,992 titled, \u201cTarget for Regulating Multiple Sclerosis\u201d by Graham KL, Zabel BA, Butcher EC, October 2011. In both cases, the specific aspects of the manuscript covered in the issued patents relate to the targeting of CMKLR1 with small molecule antagonist \u03b1-NETA and its analogs for the prevention and\/or treatment of demyelinating disease (e.g. MS).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"7178"}}